UK Markets closed


Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
58.35+0.02 (+0.04%)
At close: 1:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close58.33
BidN/A x N/A
AskN/A x N/A
Day's range58.35 - 58.35
52-week range34.10 - 58.96
Avg. volume2,926
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of July 31, 2021

    Declaration of the number of outstanding shares and voting rights as of July 31, 2021 Vélizy-Villacoublay (France) August 6, 2021 – Dassault Systèmes (Euronext Paris: #14003TT8, DSY.PA) reports below the total number of its outstanding shares and voting rights as of July 31, 2021, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers. Number of outstanding shares*: 1,330,538,497 Number of voting rights**: 1,991,139,902 *This number of shares take

  • Globe Newswire

    Dassault Systèmes: Availability of the 2021 Half-Year Financial Report

    Availability of Dassault Systèmes’ 2021 Half-Year Financial Report (IFRS Half-Year Consolidated Condensed Financial Statements) Vélizy-Villacoublay, France – July 27, 2021 — Dassault Systèmes (Euronext Paris: #14003TT8, DSY.PA), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions announces the availability to the public and the filing of its Half-Year Financial Report as of June 30, 2021 with the French Autorité des ma

  • Reuters

    Dassault Systemes lifts 2021 outlook on surging software sales

    The group, which makes 3D design software and technologies for manufacturing, infrastructure and healthcare groups, now expects non-IFRS revenue growth of 10%-11% this year, bringing its earnings per share to up to 0.91 euros ($1.07), adjusting for the company's five-for-one stock split earlier this month. The company noted strong contributions from its transport and mobility software as well as its life sciences business, which helps to manage clinical trials. Its software was used in around 400 trials related to COVID-19 treatments and vaccines for some 200 companies, finance chief Pascal Daloz told reporters in a call - including those developed by Novavax, Moderna and AstraZeneca.